Evidence map›Paper›PMID 36711835›Full record

ArticlebioRxiv : the preprint server for biology2023

The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.

Mithil Soni, Edoardo Migliori, Jianing Fu, Amer Assal, Hei Ton Chan, Jian Pan, Prabesh Khatiwada, Rodica Ciubotariu, Michael S May, Marcus Pereira and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Mithil SoniColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, New York, United States.
Edoardo MiglioriColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, New York, United States.
Jianing FuColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, New York, United States.
Amer AssalDepartment of Medicine, Blood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, New York, USA.
Hei Ton ChanColumbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Jian PanColumbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Prabesh KhatiwadaColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, New York, United States.
Rodica CiubotariuColumbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Michael S MayColumbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Marcus PereiraDepartment of Medicine, Division of Infectious Disease, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Valeria De GiorgiDepartment of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD.
Megan SykesColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, New York, United States.
Markus Y MaparaColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, New York, United States.
Pawel MuranskiColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, New York, United States.
Columbia University Irving Medical Center · USColumbia College · CANational Institutes of Health Clinical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell immunity plays a central role in clinical outcomes of Coronavirus Infectious Disease 2019 (COVID-19). Therefore, T cell-focused vaccination or cellular immunotherapy might provide enhanced protection for immunocompromised patients. Pre-existing T cell memory recognizing SARS-CoV2 antigens antedating COVID-19 infection or vaccination, may have developed as an imprint of prior infections with endemic non-SARS human coronaviruses (hCoVs) OC43, HKU1, 229E, NL63, pathogens of "common cold". In turn, SARS-CoV2-primed T cells may recognize emerging variants or other hCoV viruses and modulate the course of subsequent hCoV infections. Cross-immunity between hCoVs and SARS-CoV2 has not been well characterized. Here, we systematically investigated T cell responses against the immunodominant SARS-CoV2 spike, nucleocapsid and membrane proteins and corresponding antigens from α- and β-hCoVs among vaccinated, convalescent, and unexposed subjects. Broad T cell immunity against all tested SARS-CoV2 antigens emerged in COVID-19 survivors. In convalescent and in vaccinated individuals, SARS-CoV2 spike-specific T cells reliably recognized most SARS-CoV2 variants, however cross-reactivity against the

Identifiers

PMID36711835
PMCPMC9881858
OpenAlexW4313493251

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.